![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, January 05, 2024 11:32:54 AM
Re: Northwest Biotherapeutics Inc. v. Canaccord Genuity LLC, et al.,
No. 1:22-cv-10185
Dear Judge Woods:
We represent Plaintiff Northwest Biotherapeutics, Inc. in the above-captioned action and
write in response to Defendant Citadel Securities LLC’s letter (ECF 138) requesting a 30-day
extension of the deadline for Defendants to object to the Report & Recommendation (“R&R”)
issued by Magistrate Judge Stein (ECF 137).
Plaintiff does not believe an extension is necessary or warranted, as Defendants have long
been on notice of the exact issues covered by the R&R. The Amended Complaint, to which
Defendants’ motion to dismiss and the R&R is directed, was filed nearly nine months ago on April
10, 2023 (ECF 95). Defendants filed their motion to dismiss three months later on July 12, 2023
(ECF 114, 115), Plaintiff’s opposition was filed on August 25, 2023 (ECF 123), and Defendants
replied on September 27, 2023 (ECF 124). An extensive oral argument was held before Magistrate
Judge Stein on November 14, 2023.
Defendants claim that an extension is needed for them to coordinate among themselves,
but Defendants’ army of lawyers – seven firms and twenty-nine counsel of record – are more than
sufficiently equipped to timely respond to the same issues in the R&R that they briefed and argued
months ago.
While Plaintiff opposes an extension of the current briefing schedule, to the extent the
Court grants such an extension, Plaintiff respectfully requests that any extension of time to file
objections to the R&R apply to all parties, not just Defendants. The alignment of all parties’
deadlines to file objections will ensure that those objections, and any oppositions thereto, are
coordinated on a single schedule.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM